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Giant cell arteritis (GCA) can be classified into Cranial(C)-GCA and Large Vessel(LV)-GCA.
Based on analysis of temporal arteries, GCA is postulated to be T-cell-mediated.
Recently, a disturbed B-cell homeostasis was documented in newly diagnosed
GCA patients. In the current study, we assessed the presence of B-cells and
their level of ectopic organization in the aorta of LV-GCA patients. Aorta tissue
samples of 9 histologically-proven LV-GCA patients and 22 age- and sex-matched
atherosclerosis patients who underwent aortic aneurysm surgery were studied by
immunohistochemistry. Sections were stained for B-cells, T-cells, follicular dendritic cells,
high endothelial venules, germinal center B-cells, proliferating B-cells, macrophages,
and plasma cells. Aortas of LV-GCA patients showed massive infiltration of B-cells,
which clearly outnumbered T-cells, as opposed to C-GCA patients where, as previously
reported, T-cells outnumber B-cells. B-cells were mainly found in the adventitia of the
vessel wall and were organized into artery tertiary lymphoid organs. These tertiary
lymphoid organs had germinal centers, proliferating B-cells and plasma cell niches. In
conclusion, we found massive and organized B-cell infiltrates in the aorta of LV-GCA
patients, which is in line with the previously documented decrease of circulating B-cells
in active GCA. Our data indicate a role for B-cells in the pathogenesis of GCA and
thus evoke further investigation into the factors determining the tissue tropism and
organization of B-cells in GCA.
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INTRODUCTION
Giant cell arteritis (GCA) can be classified into Cranial(C)-GCA and Large Vessel(LV)-GCA.
Even with modern imaging techniques, diagnosing LV-GCA remains difficult due to its
non-specific clinical symptoms, such as weight loss or fever. LV-GCA patients can therefore present
with late stage complications such as aortic aneurysm or dissection (1). Knowledge about the
immunopathogenesis of GCA is almost exclusively based on the analysis of temporal artery biopsies
(TAB) in C-GCA. GCA is therefore regarded as a T-cell mediated disease and it is assumed that the
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immunopathogenesis at the level of the aorta is similar to the
processes in the temporal artery (2). B-cells are underexplored
in GCA due to the lack of disease specific autoantibodies and
the low number of B-cells in TAB (3, 4). However, recent
findings do suggest a role for B-cells in GCA. During active
GCA, peripheral B-cell counts were reduced and their numbers
correlated inversely with markers of systemic inflammation (5).
During treatment, B-cell counts normalized, suggesting that B-
cells are redistributed to the tissues during active disease and
return to the circulation during remission. These returning
effector B-cells demonstrated an enhanced capacity to produce
the pro-inflammatory cytokine Interleukin(IL)-6. Furthermore,
B-cells were able to organize into artery tertiary lymphoid organs
(ATLOs) in TAB from C-GCA patients (6, 7). ATLOs were also
documented in other vasculitides that can affect the aorta, like
Takayasu Arteritis (8) as well as in atherosclerosis (9). The data
indicated that B-cells are more involved in the pathology of GCA




In this retrospective study, aorta tissue samples of 9
histologically-proven LV-GCA patients and 22 age- and
sex-matched atherosclerosis patients who underwent aortic
aneurysm surgery were studied. Patients’ clinical and laboratory
data at time of surgery were extracted from medical records.
All procedures were in compliance with the Declaration
of Helsinki. Consent from the Internal Review Board and
written patient consent were not required under the Dutch
law for human medical research (WMO) since this is a
retrospective, non-interventional study. Patients were informed
that obtained medical data could be used for research purposes
in accordance with privacy rules. Number Research Register
UMCG: 201800370.
Histopathology and Immunohistochemistry
Aorta tissue was formalin fixed, paraffin embedded and
sectioned at 3µm thickness. Every first section was stained
for Hematoxylin & Eosin (H&E). Consecutive sections were
deparaffinized in xylene and rehydrated with graded ethanol.
Antigen retrieval was performed and followed by endogenous
peroxidase blockade. Staining with antibodies detecting CD20
(B-cells), CD3 (T-cells), CD21 [follicular dendritic cells (FDC)],
Peripheral node Addressin [PNAd, high endothelial venules
(HEV)], CD68 (macrophages), CD138 (plasma cells) was
performed. See Supplementary Material (Table S1) for all
antibodies and antigen retrieval methods used. Sections were
incubated with primary anti-human antibodies for 60min at
room temperature. Next, sections were incubated with secondary
antibodies for 30min. Secondary antibodies used were rabbit
anti-mouse HRP (DAKO P0260, 1:50), rabbit anti-rat HRP
(DAKO P0450, 1:50) and rabbit anti-mouse UltraVision One
detection system HRP polymer (Thermo Fisher Scientific TL-
125-PHJ). After incubation sections were treated with DAB for
visualization and counterstained with hematoxylin.
Staining for B-cell lymphoma six protein (Bcl6, germinal
center B-cells), adipophilin (atherosclerosis, foam cells), IgM,
IgG, and IgG4 was performed on a Ventana Benchmark
platform. Appropriate negative and positive controls were used.
All stained tissue sections were scanned using a Nanozoomer
Digital Pathology Scanner (NDP Scan U 10074-01, Hamamatsu
Photonics K.K.) before being analyzed.
Immunofluorescence for Detection of
Proliferating B Cells
Double-labeling immunofluorescence staining was performed
on formalin-fixed, paraffin-embedded aortic tissue. The tissue
was deparaffinized followed by antigen retrieval. Blocking
was performed with goat serum and avidin/biotin. Primary
antibodies against CD20 and Ki-67 (Table S1) were incubated for
60min followed by 30min incubation of TRITC labeled IgG2A
(1080-03, Southern Biotech) and FITC labeled IgG1A (1070-02,
Southern Biotech) secondary antibodies, respectively. DAPI was
used to stain nuclei. Images were taken with Leica DFC345 FX.
Analysis of Tissue Staining
Analysis (blinded for diagnosis) was performed by 2 independent
investigators. Semi-quantitative scoring of CD20 staining was
performed using a 5-point scale (0 = no positive cells, 1 =
occasional positive cells, 2 = moderate number of positive cells,
3 = large number of positive cells, presence of clusters, 4 =
very large number of positive cells). To allow comparison of
CD20 and CD3, the positivity ratio (positive pixels/total number
FIGURE 1 | LV-GCA aorta with granulomatous inflammation and giant cells.
Representative image of Hematoxylin Eosin (HE) and CD68+ macrophages in
the media layer of the aorta from a LV-GCA patient. The white box shows
magnified giant cells (white arrows) in the HE staining.
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TABLE 1 | Patient characteristics of LV-GCA and atherosclerosis groups.
LV-GCA Atherosclerosis
No. of patients 9 22
Age (years): mean (SD) 67.4 (8.8) 67.6 (7.0)
Gender, no. female (%) 6 (66.7) 14 (63.6)
No. of subjects on treatment with
glucocorticoids/immunosuppression
0 0








ESR (mm/h): median (IQR)* 12.5 (3.5–27.3) 15 (4–20)
CRP (mg/L): median (IQR)# 9 (5–11) 5 (5–11)
Total length of studied aortic tissue
(mm): median (IQR)
64.7 (43.8–74) 54.1 (46.1–63.4)
Reported data is from the time of aorta surgery. *ESR; n = 6 for LV-GCA and n = 19 for
atherosclerosis. #CRP; n = 7 for LV-GCA and n = 19 for atherosclerosis. There was no
significant difference between the groups regarding age, gender, ESR, CRP, and the total
length of studied aortic tissue.
of pixels) was assessed using Aperio ImageScope software
(v12.1.0.5029, Aperio Technologies) on three areas representative
of the entire tissue, selected based on the H&E staining. ATLO
scoring was performed on tissues with a B-cell score of ≥3.
A lymphocytic focus was scored as ATLO when it showed
co-localized clusters of B-cells and T-cells that displayed a
FDC network. Furthermore, macrophage staining was taken
into account to distinguish granulomas (CD68+) from ATLOs
(CD68-). ATLOs were analyzed for presence of germinal centers
and HEV. Plasma cells per ATLO were scored on a 3-point scale
(0 = no plasma cells, 1 = <10 plasma cells, 2 = >10 plasma
cells). Atherosclerosis severity was determined by examining
media damage at the atheromatous plaque. A 5-point scale
was used with 0 = no atherosclerosis, 1 = very mild (intima
hyperplasia with foam cells, media unaffected), 2 = mild (less
than half of media affected by atherosclerosis), 3 = moderate
(more than half of media affected by atherosclerosis), 4 = severe
(media completely destructed by atherosclerosis). In addition, the
number of plaques was documented.
Statistical Analysis
Statistical analysis was performed with the Mann-Whitney-
U-test or Fisher’s exacts test. The Wilcoxon signed rank test
was used for paired samples. Correlations were analyzed with
Spearman’s rank correlation coefficient. Analysis was performed




In the selected group of patients who presented with an
aneurysm of the aorta, diagnosis of LV-GCA was based on
histopathology. All LV-GCA patients showed granulomatous
inflammation in the media and all but one contained giant-
cells (Figure 1). None of the patients received glucocorticoids
or other immunosuppressive treatment at the time of surgery.
Two patients had chronic fatigue and one had night sweats at
the time of surgery. However, no suspicion of GCA was raised
by the cardiologist or cardio-thoracic surgeon before the surgery
of the aorta aneurysm. After the histopathological examination
of the aortic specimen, either an internist or rheumatologist
was consulted in 7 out of 9 patients. Two patients died of
complications after surgery. One patient received prednisolone
treatment for 6 weeks after surgery. The other LV-GCA patients
were not treated with glucocorticoids due to lack of clinical signs
or symptoms of active GCA, as assessed by signs and symptoms
of cranial GCA, measurement of the CRP, and/or ESR, evaluation
of a blood pressure difference between the right/left brachial
artery and/or femoral artery or 18F-fluorodeoxyglucose-positron
emission tomography (FDG-PET) scan (4 out of 9 patients).
Four of the LV-GCA patients had a suspicion of C-GCA
mentioned in their past history (5–11 years before aortic surgery).
A TAB was performed in three of these patients and was
positive in one patient. Of these 4 patients, one improved
spontaneously (e.g., without glucocorticoid treatment) and 3
received prednisolone treatment at diagnosis. Unfortunately,
the precise treatment duration could not be established
retrospectively. The C-GCA patient with the positive TAB
mentioned persistent fatigue after cessation of prednisolone
treatment for C-GCA.
As a control, aorta tissue of age and sex matched
atherosclerosis patients who presented with an aneurysm
was taken into account. Detailed patient characteristics are
shown in Table 1.
B-Cells Accumulate in the Aorta of LV-GCA
Patients and Outnumber T-Cells
Massive infiltrates of B-cells were observed in the aorta of
LV-GCA patients (Figure 2A). Most B-cells were observed
in the adventitial layer. Two patterns of infiltrating B-cells
were distinguished, an unorganized diffuse pattern and an
organized clustered pattern. There were significantly more B-
cells in the media and adventitia of LV-GCA patients compared
to atherosclerosis patients (Figure 2B). LV-GCA patients had
significantly more B-cell clusters per patient (Figure 2C). While
T-cells clearly outnumber B cells in temporal artery tissue, B-
cells clearly outnumbered T-cells in the aorta of LV-GCA patients
(Figure 2D). There were significantly more B-cells compared to
T-cells in the adventitia (Figure 2E).
B-Cells in the Aorta of LV-GCA Patients
Organize Into ATLOs
Aortas were further assessed for organization into ATLOs
(Figure 3A). ATLOs were present in 77.8% of LV-GCA tissues
as opposed to 36.4% of atherosclerosis tissues (Figure 3B). All
ATLOs were located in the adventitial layer, close to the media. In
LV-GCA patients, ATLOs were localized at a level corresponding
to a granuloma in themedia in 53% of cases.We also documented
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FIGURE 2 | B-cells outnumber T-cells in aorta tissue from LV-GCA patients. (A) Representative images of CD20+ B-cells (upper panel) and CD3+ T-cells (lower
panel) in the aorta of LV-GCA patients. I, intima; M, media; A, adventitia. (B) Semi-quantitative analysis of CD20+ B-cell abundance in aorta of LV-GCA and
atherosclerosis patients for the intima (int), media (med), and adventitia (adv). Scoring was performed on a 5-point scale with 0 = no positive cells, 1 = occasional
positive cells, 2 = moderate number of positive cells, 3 = large number of positive cells (clusters), 4 = very large number of positive cells. (C) The number of B-cell
clusters (semi-quantitative score ≥3) in the tissue per patient. The line depicts the median. (D) Overall CD20 and CD3 positivity for the aorta, as quantified by pixel
count of tree representative areas per tissue (n = 9). (E) CD20 and CD3 expression for the intima, media and adventitia of the aorta as quantified by pixel count. Three
representative areas per tissue (n = 9) were analyzed. In the box and whisker plots (Tukey), boxes indicate median values and interquartile ranges. The Mann-Whitney
U-test was used to compare both groups in (B,C), the Wilcoxon signed rank test was used in (D,E). *P < 0.05, **P < 0.01.
the presence of germinal centers in ATLOs in 66.7% of LV-
GCA aortas compared to 27.3% of atherosclerosis aortas (p =
0.06). All tissues containing ATLOs showed PNAd+ HEV at the
border of T-cell rich areas (Figure 3A). The number of ATLOs
per patient was significantly higher in LV-GCA (Figure 3C).
Furthermore, the number of ATLOs containing a germinal center
was also significantly higher in LV-GCA aortas (p = 0.02).
To exclude that observed differences in ATLO presence were
associated with atherosclerosis instead of GCA, atherosclerosis
severity was scored in all patients. We found no significant
differences between the LV-GCA and atherosclerosis group
regarding atherosclerosis severity. Percentages of atherosclerosis
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FIGURE 3 | ATLOs in the aorta of LV-GCA and atherosclerosis patients. (A) Representative images of consecutive sections of aorta tissue showing in brown B-cells
(CD20), T-cells (CD3), FDC (CD21), GCs (bcl6), and HEV (PNAd). The upper panel shows an ATLO without GC (bcl6–) and the lower panel an ATLO with GC (bcl6+).
(B) Relative frequency of patients with ATLOs (ATLO+) and without ATLOs (ATLO–) in the aorta for both LV-GCA and atherosclerosis patients. (C) Number of ATLOs
per 20mm of aortic tissue for both LV-GCA and atherosclerosis patients. (D) Lack of association between atherosclerosis (number of plaques) and the number of
ATLOs for LV-GCA patients. Fischer’s exact test was used in (B), Mann-whitney U-test in (C) and Spearmans r was used for (D). *P < 0.05.
severity score 1, 2, 3, and 4 were, respectively: 33, 33, 22, and
11% for the LV-GCA group and 23, 36, 18, and 23% for the
atherosclerosis group. Furthermore, no association was found
between the number of atherosclerotic lesions and the number
of ATLOs from LV-GCA patients (Figure 3D). To determine
if B-cells and ATLOs were also present in the positive TAB
from the LV-GCA patient that experienced C-GCA 5 years
before aortic surgery, we stained the TAB for B-cells, T-cells,
and FDC networks (Figure 4A). B-cells were presented on three
different areas of the adventitia/media border. These B-cells
were clustered in one location and unorganized diffuse in the
other two locations. T-cells were abundantly present at the same
areas as the B-cells. FDC networks could not be detected inside
the TAB. This data indicate a degree of T/B cell organization
in the TAB of this patient, however not (yet) as ATLO. This
patient did show ATLO formation in the adventitia of the
aorta (Figure 4B).
Plasma Cells and Proliferating B-Cells Are
Present in the ATLOs of LV-GCA Patients
Staining with CD138 was performed to assess the presence of
plasma cell niches which is a feature of ATLOs (Figure 5A).
There were strikingly more ATLOs containing plasma cell
niches in LV-GCA than in atherosclerosis tissues (Figure 5B).
In addition, ATLOs from LV-GCA had a higher number of
plasma cells in the niche compared to atherosclerosis tissues
(Figure 5C).Most plasma cells expressed IgG and only aminority
was positive for IgM. Only a small number of the IgG+ plasma
cells expressed IgG4 (data not shown), excluding an IgG4-related
aortitis. To assess if B-cells within the ATLOs are proliferating,
double staining of CD20 and proliferation marker Ki-67 was
performed and showed clear co-localization of these markers
(Figure 6). In LV-GCA, Ki-67+ cells were also observed in B-cell
rich areas that did not qualify as ATLO and in ATLOs without a
germinal center.
DISCUSSION
Our data show massive infiltration of B-cells in the aorta of
LV-GCA patients presenting with an aneurysm of the aorta. In
the majority of patients, these B-cell infiltrates were organized
into ATLOs with germinal centers and plasma cell niches. So far,
knowledge of the inflammatory infiltrate in GCA has largely been
based on temporal artery biopsies (TAB). However, in contrast
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FIGURE 4 | B-cell, T-cell and FDC network staining in TAB and aorta tissue from one patient who experienced C-GCA 5 years before aneurysm surgery.
Immunohistochemical stainings show from left to right, CD20+ B-cells, CD3+ T-cells, and no CD21+ FDC network in consecutive sections of a GCA positive TAB
(A) and CD20+ B-cells, CD3+ T-cells and a clear CD21+ FDC network in consecutive sections of GCA positive aorta (B).
FIGURE 5 | Plasma cells in ATLOs of LV-GCA and atherosclerosis patients. (A) Representative image of an ATLO with CD138+ plasma cells in niches (brown).
(B) Histogram showing the frequency of plasma cell niches per ATLO. CD138-: no plasma cells present, CD138+: plasma cells present. (C) Histogram showing the
frequency distribution of plasma cell score. Plasma cells were scored semi-quantitatively by 2 independent investigators on a 3-point scale (0–2) with 0 = no positive
cells, 1 = few positive cells (<10), and 2 = moderate to large number of positive cells (>10). Fischer’s exact test was used in (B) and the Mann-Whitney U-test was
used in (C). ****P < 0.0001.
to C-GCA, we found a dominance of B-cells over T-cells in the
aorta of LV-GCA. These data suggest a preferential migration of B
cells to the aorta (i.e., large arteries) instead of the temporal (i.e.,
cranial) arteries, which may be related to a different chemokine
and chemokine receptor expression in the aorta as compared
to the cranial arteries. The massive presence of B-cells in the
aorta strongly support a role for B-cells in the pathogenesis of
LV-GCA.
In the majority of LV-GCA aortas (78%) B-cells were
organized into ATLOs. GCA is a disease of the elderly and thus
coexistence with atherosclerosis is expected. While the presence
of ATLO in atherosclerosis is well-known, (9) we demonstrated
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FIGURE 6 | Locally proliferating B-cells in ATLOs of LV-GCA patient. Immunofluorescence staining showing from left to right: single staining for B-cells (CD20, red),
single staining for proliferation marker Ki-67 (green), double staining for B-cells, and proliferation maker Ki-67 together with DAPI staining of nuclei (blue).
that our findings were not dependent on atherosclerosis. We
observed a varying degree of organization in the aortic wall of
LV-GCA patients; ranging from B- and T-cell aggregates to highly
organized ATLOs containing a FDC network, HEV and germinal
centers. This is in line with previously reported developmental
stages of tertiary lymphoid organs (TLO) (10). All ATLOs were
located in the adventitia, mostly at the border with the media.
In the positive TAB of the patient that experienced C-GCA in the
past we found B- and T-cell aggregates in the adventitia. However,
no ATLO was found in this TAB and T-cells were more abundant
than B-cells.
In atherosclerosis, ATLOs are reported to develop at the
adventitial site opposite to the plaque (11). Remarkably,
approximately half of the ATLOs in LV-GCA were located
adjacent to a granuloma. Granulomas were found in all LV-GCA
tissues. Interestingly, in aorta tissues from Takayasu Arteritis,
only 29% of the patients displayed granulomas while ATLOs
were found in 85% (8). The high abundance of granulomas
in the aortic wall of LV-GCA patients reflects ongoing silent
vascular inflammation, despite the lack of clinical symptoms.
This observation is in line with the findings of Maleszewski
et al. showing persistent inflammation in a second TAB at 12
months in 44% of GCA patients, despite treatment-induced
clinical and biochemical remission (12). Ongoing silent vasculitis
rather than early damagemay be responsible for the development
of aneurysm and dissection in LV-GCA.
Remarkably, most of the ATLOs in GCA patients contained a
germinal center with proliferating B-cells. In secondary lymphoid
organs, germinal centers are sites of class switching, affinity
maturation, and B-cell differentiation (9, 13). The adventitial
ATLOs of LV-GCA patients contained proliferating B-cells
indicating local activity of B-cells within the germinal centers.
The LV-GCA ATLOs also consistently contained plasma cells
(95%) as opposed to ATLOs in atherosclerotic aortas (68%). The
presence of active germinal centers and associated plasma cell
niches suggest that humoral immunemechanisms are involved in
LV-GCA. Auto antibodies related to the inflammatory response
(e.g., not disease specific), including anti-ferritin and anti-
endothelial cell antibodies have been documented in GCA (14–
17), however, no disease-specific autoantibodies have been found
so far.
Alternatively, B-cells may be involved in an autoantibody-
independent manner. IL-6, a prominent cytokine in GCA,
is produced with enhanced capacity by effector B-cells
returning to the circulation after glucocorticoid-induced
remission (5). Emerging data indicate that B-cell cytokines
can modulate T-cell responses (18) and B-cells have been
shown to augment T-cell-mediated autoimmune responses
by IL-6 secretion (19). B-cells could thus contribute to
the pro-inflammatory environment and help shape T-cell
responses.
Our findings of organized B-cell architecture in LV-
GCA may be related to disease duration. In chronic
inflammation TLO can arise (13), and this likely applies
to LV-GCA patients where diagnosis can be delayed
or missed due to non-specific symptoms. In C-GCA,
diagnosis is set sooner and treatment starts immediately
to prevent blindness. In the positive TAB of one patient,
we did observe a degree of B/T cell co-localization which
is the first step toward ATLO formation. This specific
patient complaint of persistent fatigue after cessation of
glucocorticosteroid treatment and aortic aneurysm surgery was
performed 5 years later. In the aorta tissue of this specific
patients we also observed extensive B-cell infiltration
and ATLO formation suggesting that disease duration
could indeed be important. B-cells and ATLOs could be a
target for imaging in these difficult to diagnose LV-GCA
patients.
The major strength of our study is the comprehensive
immunohistochemistry analysis in an unique cohort of
LV-GCA patients compared with age and sex-matched
atherosclerosis patients. This study is limited by the small
number of aortic tissue studied. LV-GCA patients rarely
undergo aortic surgery which limits the amount of tissue
available for research. Another limitation is the retrospective
nature of the study, with limited clinical data and no blood
biobanking of these patients being available before aortic
surgery.
In conclusion, aortas of LV-GCA patients show massive
infiltration of B-cells that outnumber the T-cells and can organize
into ATLOs at the adventitial site, with germinal centers,
proliferating B-cells, and plasma cell niches. Our data strongly
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suggest a role for B-cells in the pathogenesis of GCA and thus
urge further investigation into the factors determining the tissue
tropism, organization and function of B-cells in different stages
of GCA.
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